News

Trajenta (linagliptin) and Basaglar (insulin glargine) continue to be part of the Alliance, with primary responsibility for development and commercialisation led by the innovator company. Boehringer Ingelheim will

Based on an entirely new mechanism of action, ISB 830 has the potential to treat a range of autoimmune diseases beyond atopic dermatitis. Enrollment in a large randomized

PEGPH20 was being assessed in combination with ABRAXANE (nab-paclitaxel) and gemcitabinein in the HALO-301 study as a first-line therapy for the condition. The late-stage trial enrolled 500 patients

RedHill said that its Talicia has been indicated for oral administration in the form of delayed-release capsules in 10mg, or 250mg or in 12.5mg dosage. RedHill Biopharma chief

The Phase 1 trial will evaluate single and multiple ascending doses of oral BCX9250 in healthy volunteers. The company expects to report the results from the trial in

Cosentyx, which is an inhibitor of interleukin-17A (IL-17A), could not show statistical significance for superiority in ACR 20 over the AbbVie drug in the head-to-head late-stage trial. As

BeiGene is a research-based, oncology-focused biotechnology company with an established and highly experienced team in China, including a 700-person commercial organization and a 600-person clinical development organization. “This

The study is the first in the strategic oncology partnership announced between Daiichi Sankyo and Sarah Cannon, designed to expedite and optimize global clinical development of Daiichi Sankyo’s

This agreement covers four products in rare metabolic and neurological disorders and each product will utilise Catalent’s Zydis® oral disintegrating tablet (ODT) and Zydis Ultra® technologies. Zydis technology